Pathologic Responses Result From Neoadjuvant SBRT Plus Cemiplimab in Resectable HCC
January 11th 2024Three patients with resectable hepatocellular carcinoma experienced significant tumor necrosis greater than 70% after neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc, in addition to adjuvant cemiplimab.
LUMINANCE Study Supports Durvalumab Plus Platinum/Etoposide in Frontline Treatment of ES-SCLC
January 10th 2024Findings from the phase 3b LUMINANCE study aligned with safety and efficacy outcomes from the phase 3 CASPIAN trial, both of which focused on the administration of 5 or more cycles of induction platinum/etoposide alongside durvalumab for the treatment of patients with extensive-stage small cell lung cancer.
Tisotumab Vedotin sBLA Granted Priority Review by FDA for Recurrent/Metastatic Cervical Cancer
January 10th 2024A supplemental biologics license application has been granted priority review by the FDA, which seeks a full approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer that progressed on or following frontline therapy.
Lenvatinib-Pembrolizumab Combo May Not Improve Survival vs. Docetaxel in Stage IV NSCLC
January 9th 2024A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
Tremelimumab/Durvalumab Plus Chemo Improves Survival in Metastatic NSCLC
January 8th 2024Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.